Sandipkumar S. Kapadia

Sandipkumar S.
Kapadia currently serves as Independent Non-Executive Director at Molecular Partners AG since 2020 and at Passage Bio, Inc. since 2019.
Holds director positions at Intercept Pharma Europe Ltd., Molecular Partners, Inc., and Alentis Therapeutics AG.
Serves as President of Harmony Biosciences Management, Inc. Former roles include Director at Intercept Pharma UK & Ireland Ltd. (2017–2021), Co-Managing Director at Advanz Pharma Specialty Medicine Deutschland GmbH, Director at Therachon AG, Independent Director at VectivBio Holding AG (2020–2023), Director at VectivBio AG (2020–2023), Chief Financial Officer & Vice President at Sandoz, Inc. (2014–2016), Chief Financial Officer & Treasurer at Intercept Pharmaceuticals, Inc. (2016–2021), Chief Financial Officer & Vice President at Novartis Pharmaceuticals UK Ltd. and Novartis Pharmaceuticals BV (2009–2012), Head-Finance at Novartis Pharmaceuticals Corp.
and Novartis Pharmaceuticals AG, Member-Supervisory Board at Therachon Holding GmbH, Chief Financial Officer at Harmony Biosciences LLC (2021–2026), and Chief Financial & Administrative Officer at Harmony Biosciences Holdings, Inc. (2023–2026).
Education includes an MBA from Rutgers State University of New Jersey and undergraduate studies at Montclair State University.